Operating Margin

Bionano's 2026 virtual event will showcase how Optical Genome Mapping is revolutionizing cancer and genetic disease research and paving a path to clinical use.

Activist investor Impactive Capital nominates four directors to the WEX board, citing years of underperformance and demanding a strategic overhaul.

As ReNew prepares its Q3 FY26 report, all eyes are on the energy giant. Will its performance validate India's green transition and its own manufacturing bet?

IN8bio promotes Kate Rochlin to President, signaling a strategic push to advance its promising gamma-delta T cell pipeline amid a challenging market.

With a promising spinal cord injury drug nearing late-stage trials, NervGen appoints interim leader Dr. Adam Rogers as permanent CEO to guide the breakthrough.

The Middle East healthcare giant posts record profits and a $163M dividend, fueled by aggressive international acquisitions and a major bet on AI technology.

Schweiter Technologies will unveil its 2025 results and 2026 strategy on Feb 27, with investors eager for signs of growth and profitability.

Pan-European exchange reports a strong start to 2026, fueled by a historic defense IPO and a dramatic spike in foreign exchange and metals trading.

As Timbercreek Financial preps its Q4 report, investors eye dividend health and asset quality as key indicators for the broader CRE market's new cycle.

The medical device giant posts 6% Q1 growth but faces major challenges from US reimbursement changes and a China recall, banking on a new acquisition.

Horizon Media's new HorizonOS integrates Intent IQ's identity tech to unlock valuable, hard-to-reach audiences on iOS, CTV, and cookieless browsers.

The high-tech wheel maker's stock plummets 65% as it fails to meet listing rules, signaling deep financial and operational distress for the company.

A new bond issue strengthens Agilyx's finances, funding a dual strategy focused on immediate earnings and long-term tech licensing in plastic recycling.

Amid soaring aerospace demand and strong financials, the critical component supplier will outline its tech and market strategy at its March 10 investor day.

Industrial conglomerate Schouw & Co. offers a fee for bondholder consent to spin off its aquaculture giant BioMar, a move that could unlock value but alters risk.

Mawson Infrastructure reports a steep Q4 revenue drop but a smaller annual loss, clearing major legal hurdles to focus on its AI and green energy future.

As HUTCHMED prepares to unveil its 2025 financials, investors weigh a complex picture of global drug success, domestic pressures, and pipeline promise.

With its Q4 results announcement imminent, specialty insurer Trisura is under scrutiny to prove it can sustain growth amid market pressures and investor concerns.

With a new focus on eye disease and fresh funding, Surrozen will present its novel Wnt-based pipeline to investors. What's at stake for the future of sight?

The biotech celebrates its first FDA drug approval, a massive financial boost, and promising new therapies targeting obesity and Alzheimer's disease.